Yu Nishida
Osaka City University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Yu Nishida.
PLOS ONE | 2017
Yu Nishida; Shuhei Hosomi; Hirokazu Yamagami; Tomomi Yukawa; Koji Otani; Yasuaki Nagami; Fumio Tanaka; Koichi Taira; Noriko Kamata; Tetsuya Tanigawa; Masatsugu Shiba; Kenji Watanabe; Kazunari Tominaga; Yasuhiro Fujiwara
Objectives Neutrophil-to-lymphocyte ratio (NLR) has been used to determine the outcome in malignancies and coronary heart disease. Some reports considered the value of NLR as a predictor of response to infliximab in patients with Crohn’s disease or rheumatoid arthritis; however, no similar studies have been reported for ulcerative colitis (UC). This study aimed to evaluate the clinical significance of the baseline NLR in patients with UC treated by infliximab. Materials and Methods Patients with moderate-to-severe active UC who received the first infliximab infusion in our hospital between 2010 and 2015, who showed clinical response during the induction period, were retrospectively evaluated for long-term outcomes and risk factors for loss of response (LOR) during infliximab maintenance therapy. Baseline inflammatory markers including NLR were measured within one week before the initiation of infliximab. Results Fifty-nine patients with moderate-to-severe active UC started treatment with infliximab and 37 patients (62.7%) experienced clinical response after induction therapy. Fourteen of 37 patients on maintenance therapy lost the response during follow-up. Baseline NLR of patients with LOR was significantly higher than in patients with sustained response. The NLR cut-off value of 4.488 was predictive of LOR, using receiver operating characteristic analysis (sensitivity: 78.6%, specificity: 78.3%). A univariate analysis revealed a significant relationship between relapse-free survival and the NLR (P = 0.018). Multivariate analysis indicated the NLR as an independent prognostic factor for LOR (hazard ratio = 3.86, 95% confidence interval: 1.20–12.4, P = 0.023). Conclusions Baseline NLR is a useful prognostic marker in patients with moderate-to-severe active UC treated with infliximab, and may contribute to appropriate use of infliximab.
Romanian Journal of Internal Medicine | 2017
Hirokazu Yamagami; Yu Nishida; Yasuaki Nagami; Shuhei Hosomi; Tomomi Yukawa; Koji Otani; Fumio Tanaka; Koichi Taira; Noriko Kamata; Tetsuya Tanigawa; Masatsugu Shiba; Yasuhiro Fujiwara
Abstract Introduction. Both infliximab (IFX) and tacrolimus (Tac) are effective for inducing clinical remission in patients with ulcerative colitis (UC). However, no randomized study has addressed the relative efficacies of IFX and Tac for patients with moderate to severe UC. This study aimed to conduct a retrospective study on the relative efficacy of IFX and Tac in patients with moderate to severe UC, using an inverse probability of treatment weighting (IPTW) technique to adjust background factors statistically. Methods. Between July 2009 and March 2016, data obtained from 122 patients with moderate to severe UC who were treated with either IFX (n = 58) or Tac (n = 64) were analyzed retrospectively. We compared the short-term therapeutic efficacy between the IFX group and Tac group using IPTW technique. Results. The clinical remission rate at 14 weeks after treatment was 37.9% (22/58) in the IFX group and 50% (32/64) in the Tac group, respectively. The efficacy of IFX and Tac for clinical remission rate was not different according to univariate (Odds ratio [OR] 1.64, 95% confidence interval [CI] 0.80-3.37 P = 0.18) and multivariate analyses (OR 2.19, 95% CI 0.85-5.61, P = 0.10). After the background and confounders factors were adjusted by using IPTW based on propensity score, the efficacy of IFX and Tac for clinical remission rate was not differed statistically (OR, 1.483; 95% CI, 0.581-3.785; P = 0.409) Conclusion. IFX and Tac have equivalent short-term efficacies for induction in patients with moderate to severe UC.
Internal Medicine | 2017
Yu Nishida; Shuhei Hosomi; Hirokazu Yamagami; Tomomi Yukawa; Yasuaki Nagami; Fumio Tanaka; Noriko Kamata; Tetsuya Tanigawa; Masatsugu Shiba; Toshio Watanabe; Kazunari Tominaga; Yasuhiro Fujiwara; Tetsuo Arakawa
Objective Balloon-assisted endoscopy enables access to and treatment of strictures in the small intestine using endoscopic balloon dilation (EBD); however, the long-term outcomes of EBD have not been sufficiently evaluated. This study evaluated the long-term outcomes of EBD in Crohns disease to identify the risk factors associated with the need for subsequent surgical intervention. Methods We retrospectively analyzed patients with Crohns disease who had undergone EBD with double-balloon endoscopy (DBE) for small intestinal strictures at a single center between 2006 and 2015. The long-term outcomes were assessed based on the cumulative surgery-free rate following initial EBD. Results Seventy-two EBD with DBE sessions and 112 procedures were performed for 37 patients during this period. Eighteen patients (48.6%) required surgery during follow-up. Significant factors associated with the need for surgery in a multivariate analysis were multiple strictures (adjusted hazard ratio, 14.94; 95% confidence interval, 1.91-117.12; p=0.010). One patient (6.7%) required surgery among 15 who had single strictures compared to 17 (77.3%) among 22 patients with multiple strictures. Conclusion In a multivariate analysis, the presence of multiple strictures was a significant risk factor associated with the need for surgery; therefore, a single stricture might be a good indication for EBD using DBE for small intestinal strictures in Crohns disease patients.
Scandinavian Journal of Gastroenterology | 2018
Yu Nishida; Shuhei Hosomi; Kenji Watanabe; K. Watanabe; Tomomi Yukawa; Koji Otani; Yasuaki Nagami; Fumio Tanaka; Koichi Taira; Noriko Kamata; Hirokazu Yamagami; Tetsuya Tanigawa; Toshio Watanabe; Yasuhiro Fujiwara
Abstract Objectives: Infliximab is effective in patients with ulcerative colitis (UC); however, one-third of patients do not respond and require additional therapies such as other biologic agents. Therefore, the aim of this study was to analyze the association between pro-inflammatory molecules and clinical efficacy to elucidate possible mechanisms for the non-response to infliximab to aid in treatment selection. Materials and method: Patients with moderate-to-severe active UC receiving infliximab in our hospital between 2010 and 2016 for whom pre-treatment serum samples were available were retrospectively evaluated. We analyzed the association between serum interleukin (IL)-6, tumor necrosis factor-α (TNF-α) and soluble mucosal vascular addressin cell adhesion molecule-1 (sMAdCAM-1) and the clinical efficacy of infliximab. The primary endpoint was clinical response at the end of the induction period. Results: Forty-one patients were included in this study. After induction therapy, 27 patients (65.9%) showed a clinical response. Serum IL-6 levels were significantly lower in responders than in non-responders (p = .012), whereas no significant differences were noted in other factors including sMAdCAM-1 and TNF-α. Multivariate analysis identified that serum IL-6 level (odds ratio = 0.72; 95% confidence interval, 0.54–0.96; p = .027) was independently associated with response to infliximab. Conclusions: Serum IL-6 level is associated with response to infliximab in UC. Elevated concentrations of IL-6 may provide insight to the mechanism of non-response to infliximab.
Inflammatory Bowel Diseases | 2018
Shuhei Hosomi; Kenji Watanabe; Yu Nishida; Hirokazu Yamagami; Tomomi Yukawa; Koji Otani; Yasuaki Nagami; Fumio Tanaka; Koichi Taira; Noriko Kamata; Tetsuya Tanigawa; Masatsugu Shiba; Toshio Watanabe; Hisashi Nagahara; Kiyoshi Maeda; Yasuhiro Fujiwara
Background Little is known about the prevalence and pathogenicity of human herpes viruses except for cytomegalovirus (CMV) in patients with inflammatory bowel disease (IBD). The aim of this study was to determine the prevalence of human herpes viruses on colonic mucosa in patients with IBD and assess the long-term outcomes in these patients. Methods We examined the colonic mucosal specimens from 66 patients with ulcerative colitis (UC), 54 patients with Crohns disease (CD), and 29 healthy patients to identify the 6 most common types of human herpes virus, using multiplex polymerase chain reaction (PCR) technique. Results Herpes simplex virus (HSV)-1/2 and varicella-zoster virus (VZV) were not detected in any of the groups. There was a higher prevalence of Epstein-Barr virus (EBV) (21.2%) and CMV (15.1%) in patients with UC than in patients with CD (EBV 9.3%, CMV 0%) and patents in the healthy control group (EBV 0%, CMV 3.4%). The prevalence of human herpes virus (HHV)-6A/B and HHV-7 was not statistically different among the groups. Five UC patients with inflammation had coexisting CMV and EBV or HHV-6. The combined infection of CMV with EBV or HHV-6 was a significant and independent prognostic factor for subsequent colectomy in patients with UC. Conclusions The increased prevalence of CMV coexisting with EBV/HHV-6 infection was associated with the clinical course in patients with UC. 10.1093/ibd/izy005_video1izy005_Video_15786489376001.
Journal of Medical Cases | 2016
Chikae Isayama; Nobuhiro Takeuchi; Masanori Takada; Yu Nishida; Yusuke Nomura; Masato Iida; Akihito Otsuka
Gastrointestinal perforation is an emergency condition commonly caused by benign ulcers, diverticulosis, or gastrointestinal malignancies; however, primary intestinal malignant lymphoma (PIML) is a rare etiology. We herein report a case of primary T-cell lymphoma with small intestinal perforation. J Med Cases. 2016;7(12):539-542 doi: https://doi.org/10.14740/jmc2690w
journal of Clinical Case Reports | 2014
Nobuhiro Takeuchi; Yusuke Nomura; Yu Nishida; Tetsuo Maeda; Hidetoshi Tada; Kazuyoshi Naba
A 72-years-old male visited our institution because of severe abdominal distention. Abdominal computed tomography revealed liver cirrhosis with massive retention of ascites. Ascites was treated using diuretic drugs and albumin preparation. Gastroendoscopy revealed esophageal varices, which was successfully treated with endoscopic variceal ligation. A follow-up gastroendoscopy performed 4 months later revealed the disappearance of esophageal varices and the presence of a depressed lesion on the anterior wall of the lesser curvature of the midgastric body with a small orifice near the anal side of the depressed lesion, suggesting gastric gland heterotopia. A biopsy from the depressed lesion revealed group 5. Endoscopic ultrasonography revealed anechoic lesions in the third layer and type 0-IIc lesion with invasion to the third layer, suggesting that the IIc lesion invaded thesubmucosal layers. On the basis of endoscopic findings, the IIc lesion was considered to be within the submucosal layer; therefore, Endoscopic Submucosal Dissection (ESD) was performed, and pathological findings of the resected specimen revealed moderately differentiated tubular adenocarcinoma within the mucosallayer and multiple cystic dilated lesions in the submucosal layer. The post-ESD course wasuneventful and recurrence or de novo lesion has not been detected by regular gastroendoscopy
Gastroenterology | 2018
Naoko Sugita; Tomomi Yukawa; Rieko Nakata; Yu Nishida; Shigehiro Itani; Shuhei Hosomi; Mizuki Ohira; Noriko Kamata; Koji Otani; Yasuaki Nagami; Fumio Tanaka; Koichi Taira; Hirokazu Yamagami; Tetsuya Tanigawa; Kiyoshi Maeda; Yasuhiro Fujiwara
Gastroenterology | 2017
Yu Nishida; Kenji Watanabe; Shuhei Hosomi; Hirokazu Yamagami; Koji Otani; Yasuaki Nagami; Fumio Tanaka; Noriko Kamata; Koichi Taira; Masatsugu Shiba; Kazunari Tominaga; Yasuhiro Fujiwara
Internal Medicine | 2014
Nobuhiro Takeuchi; Tetsuo Maeda; Ryota Aoki; Sayuri Tanaka; Yu Nishida; Yusuke Nomura; Hidetoshi Tada